ReviewOrthopaedic surgery2025
Research Trends in Immunomodulatory Therapy for Postmenopausal Osteoporosis: A Bibliometric Analysis.
Review in Orthopaedic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Macrophage polarization regulates bone homeostasis: a potential etiology and therapy for postmenopausal osteoporosis.Frontiers in immunology · 2026Review
- Research Trends in Immunomodulatory Therapy for Postmenopausal Osteoporosis: A Bibliometric Analysis.Orthopaedic surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This bibliometric analysis investigates the research trends in immunomodulatory therapies for postmenopausal osteoporosis from 2000 to 2024. Utilizing 950 articles retrieved from the Web of Science Core Collection, we employed CiteSpace, VOSviewer, and R-based Bibliometrix to analyze publication dynamics, collaborative networks, and thematic evolution. Key findings include: (1) a steady rise in annual publications, peaking at 82 articles in 2024, with China (265 articles) and the United States (173 articles) as leading contributors. (2) Research hotspots centered on the RANKL/RANK/OPG pathway, T-cell-mediated inflammation (e.g., Th17/IL-17 axis), and emerging topics such as gut microbiota-bone axis and mesenchymal stem cell differentiation. (3) Clinical strategies prioritized denosumab (anti-RANKL) and IL-17 inhibitors, though long-term safety requires validation. (4) Institutional collaboration spanned continents, with Emory University, Harvard University, and Sichuan University as pivotal hubs. Keyword bursts revealed a shift from foundational mechanisms (e.g., TNF-α/IL-6 signaling) to translational topics like gene editing and precision medicine. Limitations include database bias (exclusive reliance on Web of Science) and undifferentiated clinical versus preclinical studies analysis. This study underscores the transformative potential of immunotherapies in osteoporosis management while advocating for multidisciplinary integration, expanded data sources, and rigorous clinical validation to address existing gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.